Various clinical presentations of uveitis associated with durvalumab treatment
By:
References
- Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019; 394: 1929-39. doi: 10.1016/S0140-6736(19)32222-6
- European Medicines Agency. Imfinzi, INN-durvalumab. 2020. [cited 30 Nov 2020]. Available at: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf
- Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep 2017; 7: 5532. doi: 10.1038/s41598-017-06002-8
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64. doi: 10.1038/nrc3239
- Sun MM, Levinson RD, Filipowicz A, Anesi S, Kaplan HJ, Wang W, et al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm 2020; 28: 217-27. doi: 10.1080/09273948.2019.1577978
- Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes. Ocul Immunol Inflamm 2021; 29: 20311. doi: 10.1080/09273948.2020.1781902
- Parikh RA, Chaon BC, Berkenstock MK. Ocular complications of checkpoint inhibitors and immunotherapeutic agents: a case series. Ocul Immunol Inflamm 2021; 29: 1585-90. doi: 10.1080/09273948.2020.17660828
- Andrade AR, Moll-Udina A, Martin R, Cilveti E, Subirà O, Disfetano L, et al. Retinal vasculitis secondary to durvalumab. Case Rep Ophthalmol 2020; 11: 161-6. doi: 10.1159/000507609
- Hahn L, Pepple KL. Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. J Ophthal Inflamm Infect 2016; 6: 14. doi: 10.1186/s12348-016-0082-3
- Aaberg MT, Aaberg TM. Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep 2017; 11: 348-51. doi: 10.1097/ICB.0000000000000368
- Wang W, Lam WC, Chen L. Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol Immunother 2019; 68: 85-95. doi: 10.1007/s00262-018-2260-7
- Reid G, Lorigan P, Heimann H, Hovan M. et al. Management of chronic hypotony following bilateral uveitis in a patient treated with pembrolizumab for cutaneous metastatic melanoma. Ocul Immunol Inflamm 2019; 27: 1012–15. doi: 10.1080/09273948.2018.1459733
- Navarro-Perea C, Garcia-Gonzalez J, Perez-Blazquez E. Case report: bilateral uveitis and papillitis secondary to treatment with pembrolizumab. Indian J Ophthalmol 2019; 67: 2075-7. doi: 10.4103/ijo.IJO_1161_19
- Kim YJ, Lee JS, Lee J, Lee SC, Kim TI, Byeon SH, et al. Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. Cancer Immunol Immunother 2020; 69: 2241-52. doi: 10.1007/s00262-020-02635-3
- Kikuchi R, Kawagoe T, Hotta K. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol 2020; 20: 252. doi: 10.1186/s12886-020-01519-5
- Young L, Finnigan S, Streicher H, Chen HX, Murray J, Sen HN, et al. Ocular adverse events in PD-1 and PD-L1 inhibitors. J Immunother Cancer 2021; 9: e002119. doi: 10.1136/jitc-2020-002119
- Carrera W, Baartman BJ, Kosmorsky G. A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancer. Neuro-Ophthalmol 2017; 41: 140-3. doi: 10.1080/01658107.2017.1291686
- Noble CW, Gangaputra SS, Thompson IA, Yuan A, Apolo AB, Lee JM, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm 2020; 28: 854-9. doi: 10.1080/09273948.2019.1583347
- Sabini E, Sframeli A, Marinò M. A case of drug-induced Graves’ orbitopathy after combination therapy with tremelimumab and durvalumab. J Endocrinol Invest 2018; 41: 877-8. doi: 10.1007/s40618-018-0906-0
- Yang W, Li H, Chen PW, Chen HX, Murray J, Sen HN, et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci 2009; 50: 273-80. doi: 10.1167/iovs.08-2397
- Francis JH, Berry D, Abramson DH, Barker CA, Bergstrom C, Demirci H, et al. Intravitreous cutaneous metastatic melanoma in the era of checkpoint inhibition. Ophthalmology 2020; 127: 240-8. doi: 10.1016/j.ophtha.2019.09.018
- Sun MM, Seleme N, Chen JJ, et al. Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade. J Neuroophthalmol 2021; 41: 519-30. doi; 10.1097/WNO.0000000000001148
- Gordon L, Dinkin M. Paraneoplastic syndromes in neuro-ophthalmology. Continuum (Minneap Minn) 2019; 25: 1401-21. doi: 10.1212/CON.0000000000000788.
- Xu Q, Du W, Zhou H, Zhang X, Liu H, Song H, et al. Distinct clinical characteristics of paraneoplastic optic neuropathy. Br J Ophthalmol 2019; 103: 797-801. doi: 10.1136/bjophthalmol-2018-312046
- Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54: 38-50. doi: 10.1002/ana.10587
- Adamus G, Champaigne R, Yang S. Occurrence of major anti-retinal autoantibodies associated with paraneoplastic autoimmune retinopathy. Clin Immunol 2020; 210: 108317. doi: 10.1016/j.clim.2019.108317
- Yagyu K, Ueda T, Miyamoto A, Uenishi R, Matsushita H, Tanaka T. Cancerassociated retinopathy with neuroendocrine combined large-cell lung carcinoma and adenocarcinoma. Intern Med 2019; 58: 3289-94. doi: 10.2169/internalmedicine.2313-18
- Hoogewoud F, Butori P, Blanche P, Brézin AP. Cancer-associated retinopathy preceding the diagnosis of cancer. BMC Ophthalmol 2018; 18: 285. doi: 10.1186/s12886-018-0948-2
- Makiyama Y, Kikuchi T, Otani A, Oishi A, Guo C, Nakagawa S, et al. Clinical and immunological characterization of paraneoplastic retinopathy. Invest Ophthalmol Vis Sci 2013; 54: 5424-31. doi: 10.1167/iovs.13-11868
- Pepple KL, Cusick M, Jaffe GJ, Mruthyunjaya P. SD-OCT and autofluorescence characteristics of autoimmune retinopathy. Br J ophthalmol 2013; 97: 13944. doi: 10.1136/bjophthalmol-2012-302524
- Lee KM, Woo SJ, Hwang JM. Factors associated with visual field defects of optic disc. PLoS One 2018; 13: e0196001. doi: 10.1371/journal.pone.0196001
- Casado A, Rebolleda G, Guerrero L, Leal M, Contreras I, Oblanca N, et al. Measurement of retinal nerve fiber layer and macular ganglion cell–inner plexiform layer with spectral-domain optical coherence tomography in patients with optic nerve head drusen. Graefes Arch Clin Exp Ophthalmol 2014; 252: 1653-60. doi: 10.1007/s00417-014-2773-5
- Coscas G, De Benedetto U, Coscas F, Li Calzi CI, Vismara S, Roudot-Thoraval F, et al. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica 2013; 229: 32-7. doi: 10.1159/000342159
Language: English
Page range: 129 - 137
Submitted on: Nov 24, 2021
Accepted on: Jan 10, 2022
Published on: Apr 12, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2022 Nika Vrabic, Ana Fakin, Polona Jaki Mekjavic, Urska Janzic, Martina Vrankar, Natasa Vidovic Valentincic, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.